uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer. Nordic Cystectomy Trial 2
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Surgical Sciences.
Show others and affiliations
2002 In: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, Vol. 36, no 6, 419-425 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2002. Vol. 36, no 6, 419-425 p.
URN: urn:nbn:se:uu:diva-90620OAI: oai:DiVA.org:uu-90620DiVA: diva2:163049
Available from: 2003-05-16 Created: 2003-05-16Bibliographically approved
In thesis
1. Experimental Diagnostics and Therapeutics of Invasive Urinary Bladder Cancer
Open this publication in new window or tab >>Experimental Diagnostics and Therapeutics of Invasive Urinary Bladder Cancer
2003 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The two purposes of this thesis were to evaluate new diagnostic techniques of lymphnode staging in invasive bladder cancer and to evaluate the results of neoadjuvant chemotherapy in invasive bladder cancer.

Sentinel node detection was performed in 13 patients in preparation for radical cystectomy. The method showed to be feasible, and the results displayed the occurrence of metastatic nodes outside the traditional area of diagnostic dissection in a majority of patients. Four patients were metastasized, each one with one metastatic node detected with the help of the sentinel node procedure.

Four randomly selected sentinel nodes from four different unmetastasized patients were compared to the four metastatic sentinel nodes from the first series. After microdissection, p53 genomic structure, immunohistochemical expression and MVD (microvessel density) were assessed in the primary tumors and corresponding sentinel nodes. The results suggested that invasive bladder cancer mainly involved monoclonal proliferation with predominantly homogenous biomarker profile, but there were also signs of clonal evolution.

The Nordic Cystectomy Trial 2 (NCT2), is a randomized prospective trial investigating the possible benefit of neoadjuvant chemotherapy versus cystectomy only, in 311 eligible patients with urinary bladder cancer T2-T4aNXM0.Evaluation of overall survival did not show any statistically significant benefit in the experimental arm. This probably due to lack of statistical power.

To increase the statistical power we performed a combined analysis of randomized patients from both the Nordic Cystectomy Trial 1 (NCT1) and NCT2, n = 620. Eligible patients from NCT1 had T1G3, T2-T4a NXM0 urinary bladder cancer. Standard meta-analysis methods were used. The only end-point analysed was overall survival. Neoadjuvant platinum based combination therapy was associated with a 20 % reduction in the relative hazard in probability of death.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2003. 86 p.
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 0282-7476 ; 1257
Surgery, Bladder cancer, Cystectomy, Neoadjuvant chemotherapy, Kirurgi, Lymph node excision, Radionuclide imaging, Gene expression
National Category
Research subject
urn:nbn:se:uu:diva-3504 (URN)91-554-5619-7 (ISBN)
Public defence
2003-06-06, Rudbeckssalen, Rudbeckslaboratoriet, 751 85 Uppsala, 09:15
Available from: 2003-05-16 Created: 2003-05-16Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Surgical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 59 hits
ReferencesLink to record
Permanent link

Direct link